- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 2 Years to 5 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Gulf Breeze, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 2,339
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolemia
- Interventions
- lerodalcibep
- Drug
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Advanced Solid Tumors
- Interventions
- MEDI5395, Durvalumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • La Jolla, California • Rochester, Minnesota + 5 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- XL844
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Duarte, California • San Diego, California • Houston, Texas
- Conditions
- Meniere's Disease
- Interventions
- SPI-1005
- Drug
- Lead sponsor
- Sound Pharmaceuticals, Incorporated
- Industry
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more
- Conditions
- HIV Infection
- Interventions
- Griffithsin Gel, Placebo Gel
- Drug
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Healthy Volunteers
- Interventions
- AEF0117, Placebo
- Drug
- Lead sponsor
- Aelis Farma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Opiate Addiction
- Interventions
- 6β-Naltrexol escalating doses from 0.05-0.5 mg IV
- Drug
- Lead sponsor
- California Pacific Medical Center Research Institute
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Colitis, Ulcerative
- Interventions
- Ozanimod
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more
- Conditions
- Rheumatoid Arthritis, Pharmacokinetics of ASP2408
- Interventions
- ASP2408, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Anniston, Alabama • Duncansville, Pennsylvania • Dallas, Texas
- Conditions
- Breast Cancer, Solid Tumors
- Interventions
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more
- Conditions
- Relapsed/Refractory B-cell Malignancies
- Interventions
- AC676
- Drug
- Lead sponsor
- Accutar Biotechnology Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Sarasota, Florida • Chapel Hill, North Carolina + 6 more
- Conditions
- Healthy
- Interventions
- ABT-384
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- GSK376501, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
- Interventions
- MT-4561
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
- Conditions
- Asthma
- Interventions
- Mepolizumab
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Spasticity, Cerebral Palsy
- Interventions
- baclofen
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 8 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-418, TAK-418 Matching Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Glendale, California • Salt Lake City, Utah
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 2 more
- Conditions
- Phase 1 Sickle Cell
- Interventions
- PDE9i, placebo for PDE9i
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Brooklyn, New York + 2 more
- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- RO7669330, Syfovre™, Izervay™
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 14 more
- Conditions
- Healthy Participants
- Interventions
- BMS-986318, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Overweight, Diabetes Mellitus Type 2 in Obese
- Interventions
- P11187, Placebo
- Drug
- Lead sponsor
- Piramal Enterprises Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida